Zoetis secures FDA clearance for a new single‑injection antibiotic for canine skin infections
Zoetis announced that the U.S. Food and Drug Administration has approved its new ready‑to‑use formulation of Convenia for dogs. The product delivers a 14‑day course of treatment in one subcutaneous injection administered by a veterinarian. Zoetis expects the drug to reach U.S. veterinary practices in the first quarter of 2027, adding to its dermatology portfolio for medium‑ and large‑breed dogs.
Why it matters
The approval creates a future revenue stream as the product will be launched in Q1 2027, expanding Zoetis’ dermatology offerings. Analysts note that regulatory clearance often precedes sales growth, so investors can monitor launch timing and early adoption for impact on Zoetis’ top line.
Key facts
- 1The FDA approved Zoetis’ new ready‑to‑use injectable for dogs. stocktitan.net
- 2The drug provides up to 14 days of antibiotic coverage in a single subcutaneous dose. investing.com
- 3It is indicated for bacterial skin infections such as secondary superficial pyoderma, abscesses and wounds caused by susceptible Staphylococcus pseudintermedius and Streptococcus canis strains. investing.com
- 4Zoetis expects U.S. availability in the first quarter of 2027. stocktitan.net
- 5The original Convenia product has 18 years of real‑world experience, with 86% of dogs in one study resolving infection after a single injection. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.